Ziprasidone

Generic Name
Ziprasidone
Brand Names
Geodon, Zeldox
Drug Type
Small Molecule
Chemical Formula
C21H21ClN4OS
CAS Number
146939-27-7
Unique Ingredient Identifier
6UKA5VEJ6X
Background

Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior. These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers. Luckily, several treatment options for psychotic disorders have been ...

Indication

In its oral form, ziprasidone is approved for the treatment of schizophrenia, as monotherapy for acute treatment of manic or mixed episodes related to bipolar I disorder, and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder. The injectable formulation is approved only for treatment of acute agitation in schizophre...

Associated Conditions
Acute Agitation, Agitation, Bipolar 1 Disorder, Psychosis, Schizophrenia, Treatment Resistant Major Depressive Disorder, Acute Manic episode, Acute Mixed manic depressive episode
Associated Therapies
-

Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder

Phase 4
Completed
Conditions
First Posted Date
2005-08-29
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
294
Registration Number
NCT00137020
Locations
🇦🇪

Pfizer Investigational Site, Dubai, United Arab Emirates

The MIND Study: Modifying the INcidence of Delirium

First Posted Date
2004-11-17
Last Posted Date
2016-01-29
Lead Sponsor
Vanderbilt University
Target Recruit Count
102
Registration Number
NCT00096863
Locations
🇺🇸

University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

🇺🇸

University of Iowa, Iowa City, Iowa, United States

🇺🇸

Moses Cone, Greensboro, North Carolina, United States

and more 2 locations

Treatment and Outcome of Early Onset Bipolar Disorder

Phase 4
Completed
Conditions
First Posted Date
2002-11-13
Last Posted Date
2014-01-22
Lead Sponsor
Northwell Health
Target Recruit Count
40
Registration Number
NCT00048802
Locations
🇺🇸

The Zucker Hillside Hospital, Long Island Jewish Medical Center, Glen Oaks, New York, United States

Switching Medication to Treat Schizophrenia

First Posted Date
2002-09-05
Last Posted Date
2016-04-28
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
219
Registration Number
NCT00044655

Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia

First Posted Date
2002-05-03
Last Posted Date
2006-07-19
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
378
Registration Number
NCT00034801

CATIE- Schizophrenia Trial

Phase 4
Completed
Conditions
First Posted Date
2001-04-09
Last Posted Date
2015-06-17
Lead Sponsor
National Institute of Mental Health (NIMH)
Target Recruit Count
1600
Registration Number
NCT00014001
Locations
🇺🇸

Staten Island University Hospital, Staten Island, New York, United States

🇺🇸

Emory University School of Medicine, Atlanta, Georgia, United States

🇺🇸

Northwestern Medical School Department of Psychiatry, Chicago, Illinois, United States

and more 51 locations
© Copyright 2024. All Rights Reserved by MedPath